Suchergebnisse - "Fajgenbaum, David C."

PubPharm (6)

1

Anti-type I interferon antibodies as a cause of severe COVID-19

enthalten in: Faculty reviews | 2022

von Fajgenbaum, D. | Hayday, A. | Rogers, A. | +3

CommentOn: Science. 2020 Oct 23;370(6515):. - PMID 32972996

2

Optimisation of anti-interleukin-6 therapy : Precision medicine through mathematical modelling

enthalten in: Frontiers in immunology | 2022

von Rossi, J. | Chiang, H. | Lu, Z. | +5

3

Treatments Administered to the First 9152 Reported Cases of COVID-19 : A Systematic Review

enthalten in: Infectious diseases and therapy | 2020

von Fajgenbaum, D. | Khor, J. | Gorzewski, A. | +19

4

Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review

enthalten in: Infectious diseases and therapy | 2020

von Fajgenbaum, D. | Khor, J. | Gorzewski, A. | +19

5

Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review

enthalten in: Infectious diseases and therapy | 2020

von Fajgenbaum, D. | Khor, J. | Gorzewski, A. | +19

6

Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review

enthalten in: Infectious diseases and therapy | 2020

von Fajgenbaum, D. | Khor, J. | Gorzewski, A. | +19

1
[1]